经皮冠状动脉介入治疗缺血性心肌病合并严重心功能不全患者临床疗效
|
摘要
目的探讨经皮冠状动脉介入治疗缺血性心肌病合并严重心功能不全患者的临床疗效。方法回顾性分析自2015年2月至2017年6月宿州市立医院收治的90例缺血性心肌病合并严重心功能不全患者的临床资料,按照治疗方式不同,将患者分入药物治疗组(n=54)和经皮冠状动脉介入治疗组(n=36)。药物治疗组患者接受常规药物治疗;经皮冠状动脉介入治疗组患者在药物治疗组基础上,联合经皮冠状动脉介入治疗。比较两组患者治疗前和治疗后3个月的心功能分级、左心室舒张末期直径、左心室射血分数及心绞痛分级。结果治疗前,两组患者心功能分级、左心室舒张末期直径、左心室射血分数、心绞痛分级比较,差异无统计学意义(P>0.05);治疗后3个月,两组患者心功能分级、左心室舒张末期直径、左心室射血分数比较,差异无统计学意义(P>0.05);治疗前和治疗后3个月的心功能分级、左心室舒张末期直径、左心室射血分数比较,差异均无统计学意义(P>0.05);与治疗前比较,两组患者治疗后3个月的心绞痛分级明显降低,且经皮冠状动脉介入治疗组低于药物治疗组,差异有统计学意义(P<0.05)。结论与单纯药物治疗比较,联合经皮冠状动脉介入治疗能够更好地改善缺血性心肌病合并严重心功能不全患者的心绞痛症状。
引文
[1] Gray A,Mcquillan C,Menown IBA.Advances in clinical cardiology 2016:a summary of the key clinical trials[J].Adv Ther,2017,34(7):1503-1527.
[2] Freudenberger RS,Schwarz JR,Brown J,et al.Rationale,design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class Ⅲ-Ⅳ congestive heart failure[J].Expert Opin Investig Drugs,2004,13(11):1509-1516.
[3] 付敏,师聪红,张宝红.冠状动脉介入联合心脏再同步化治疗缺血性心肌病顽固性心力衰竭的临床疗效[J].中西医结合心脑血管病杂志,2014,12(3):259-260.
[4] Wu X,Housden J,MA Y.Fast catheter segmentation from echocardiographic sequences based on segmentation from corresponding X-ray fluoroscopy for cardiac catheterization interventions[J].IEEE transactions on medical imaging,2014,34(4):61-76.
[5] Nozari Y,Eshraghi A,Talasaz AH,et al.Protection from reperfusion injury with intracoronary N-acetylcysteine in patients with stemi undergoing primary percutaneous coronary intervention in a cardiac tertiary center[J].Am J Cardiovasc Drugs,2018,18(3):213-221.
[6] Magdy G,Sadaka M,Elzawawy T,et al.Effect of elective percutaneous coronary intervention of left anterior descending coronary artery on regional myocardial function using strain imaging[J].Egypt Heart J,2018,70(2):83-88.
[7] Perera D,Clayton T,Petrie MC,et al.Percutaneous revascularization for ischemic ventricular dysfunction:rationale and design of the REVIVED-BCIS2 trial:percutaneous coronary intervention for ischemic cardiomyopathy[J].JACC Heart Fail,2018,6(6):517-526.
[8] Iribarne A,Discipio AW,Leavitt BJ,et al.Comparative effectiveness of coronary artery bypass grafting versus percutaneous coronary intervention in a real-world surgical treatment for ischemic heart failure trial population[J].J Thorac Cardiovasc Surg,2018,156(4):1410-1421.
[2] Freudenberger RS,Schwarz JR,Brown J,et al.Rationale,design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class Ⅲ-Ⅳ congestive heart failure[J].Expert Opin Investig Drugs,2004,13(11):1509-1516.
[3] 付敏,师聪红,张宝红.冠状动脉介入联合心脏再同步化治疗缺血性心肌病顽固性心力衰竭的临床疗效[J].中西医结合心脑血管病杂志,2014,12(3):259-260.
[4] Wu X,Housden J,MA Y.Fast catheter segmentation from echocardiographic sequences based on segmentation from corresponding X-ray fluoroscopy for cardiac catheterization interventions[J].IEEE transactions on medical imaging,2014,34(4):61-76.
[5] Nozari Y,Eshraghi A,Talasaz AH,et al.Protection from reperfusion injury with intracoronary N-acetylcysteine in patients with stemi undergoing primary percutaneous coronary intervention in a cardiac tertiary center[J].Am J Cardiovasc Drugs,2018,18(3):213-221.
[6] Magdy G,Sadaka M,Elzawawy T,et al.Effect of elective percutaneous coronary intervention of left anterior descending coronary artery on regional myocardial function using strain imaging[J].Egypt Heart J,2018,70(2):83-88.
[7] Perera D,Clayton T,Petrie MC,et al.Percutaneous revascularization for ischemic ventricular dysfunction:rationale and design of the REVIVED-BCIS2 trial:percutaneous coronary intervention for ischemic cardiomyopathy[J].JACC Heart Fail,2018,6(6):517-526.
[8] Iribarne A,Discipio AW,Leavitt BJ,et al.Comparative effectiveness of coronary artery bypass grafting versus percutaneous coronary intervention in a real-world surgical treatment for ischemic heart failure trial population[J].J Thorac Cardiovasc Surg,2018,156(4):1410-1421.